CommercialCoverageMedium impact
Critical Flicker Fusion (CPB 0860, reviewed 2025-12-24)
Aetna·Ophthalmology, Optometry, Internal Medicine +2 more·Medical Policy
Effective date
Dec 24, 2025
We identified it
Aug 13, 2026
Summary
Aetna's policy (CPB 0860) classifies Critical Flicker Fusion (CFF) testing as experimental, investigational, or unproven for multiple clinical indications including diagnosis of visual acuity, hepatic encephalopathy, optic neuropathy, and prediction of surgical outcomes. This policy denies coverage for CFF testing across all listed indications, effective immediately.
Action Required
Effective immediately (policy dated 2025-12-24): Billing team must update claim submission rules in billing software to deny or reject any claims for Critical Flicker Fusion testing when billed to Aetna commercial plans. Front-line staff should update patient pre-visit notifications and encounter forms to alert providers that CFF testing is not a covered service for any of the listed indications (visual acuity diagnosis, hepatic encephalopathy, optic neuropathy, executive dysfunction, or surgical outcome prediction). Specifically: (1) Block CPT codes 99172 and 99173 when linked to CFF indications; (2) Deny claims with ICD-10 codes H25.011-H26.9, H35.30-H35.389, H46.00-H46.9, H47.011-H47.019, H53.141-H53.149, H53.8, K72.00-K72.91, and R41.844 when paired with CFF testing; (3) Update provider education materials noting that CFF remains experimental/unproven per Aetna policy; (4) Flag any submitted claims for CFF testing as non-covered prior to transmission to Aetna to prevent denials and patient billing issues. Providers should NOT order CFF testing for Aetna patients unless they are prepared to explain the non-covered status to patients upfront. Failure to implement these rules will result in claim denials and potential patient balance issues.